In vivo suicide gene therapy model using a newly discovered prostate-specific membrane antigen promoter/enhancer: A potential alternative approach to androgen deprivation therapy

Urology

Volumn 58, Issue 2 SUPPL. 1, 2001, Pages 132-139

  Uchida, Atsushi ^a   O'Keefe, Denise S ^a   Bacich, Dean J ^a   Molloy, Peter L ^b   Heston, Warren D W ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CSIRO   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE; PROSTATE SPECIFIC MEMBRANE ANTIGEN; VIRUS VECTOR;

ADENOCARCINOMA; ANIMAL MODEL; ANTIGEN EXPRESSION; CONFERENCE PAPER; CONTROLLED STUDY; DRUG SENSITIZATION; GENE CONSTRUCT; GENE THERAPY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; RETROVIRUS; SUICIDE GENE; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; CYTOSINE DEAMINASE; FLUCYTOSINE; GENE EXPRESSION; GENE THERAPY; GENES, REPORTER; HUMANS; LUCIFERASES; MALE; MICE; NUCLEOSIDE DEAMINASES; PRODRUGS; PROMOTER REGIONS (GENETICS); PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SIMIAN VIRUS 40; TUMOR CELLS, CULTURED;

EID: 0034898946     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(01)01256-0     Document Type: Conference Paper

References (26)

1. Adenoviral transduction of a cytosine deaminase/thymidine kinase fusion gene into prostate carcinoma cells enhances prodrug and radiation sensitivity
2. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer
3. Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer
4. In situ gene therapy for adenocarcinoma of the prostate; a phase I clinical trial
5. Liver-associated toxicity of the HSV-tk/GCV approach and adenoviral vectors
6. Severe hepatic dysfunction after adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene and ganciclovir administration
7. Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer
8. Antineoplastic effects in rats of 5-fluorocytosine in combination with cytosine deaminase capsules
9. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
10. Expression of the prostate-specific membrane antigen
11. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy
12. A tissue-specific enhancer of the prostate-specific membrane antigen gene
13. Cloning and analysis of the promoter activity of the human prostatic acid phosphatase gene
14. The promoter of the prostate-specific antigen gene contains a functional androgen responsive element
15. Evaluation of PAP and PSA gene expression in prostatic hyperplasia and prostatic carcinoma using northern-blot analyses, in situ hybridization and immunohistochemical stainings with monoclonal and biospecific antibodies
16. Prostate-specific membrane antigen expression in normal and malignant human tissues
17. Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene
18. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines; role of bone stromal cells
19. The role of stromal-epithelial interaction in normal and malignant growth
20. Transfecting well-differentiated prostatic cancer cell line LNCaP
21. Individualization of 5-fluorocytosine therapy
22. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium
23. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature
24. Prostate-specific membrane antigen is produced in tumor-associated neovasculature